Halving the price of artificial organs and bionic prostheses


The Hélice company is located in France and it aims at significantly reducing the price of bionic prostheses and artificial organs like retinal implants, neural implants, heart prothesis, exoskeletons etc,.

The development of this sector has been held back for several years, mainly because of the following factors:


– These sophisticated technologies require a very high degree of individualization.

– Several weeks and even several months are necessary to implant the prosthesis.

– Since the patient’s condition is constantly changing and because of their weakness, you have to take into account the high cost related to maintenance.

-It takes several years for new products to obtain some regulatory approval.

– Bionic prostheses are customized so large-scale production is nearly impossible.


Keeping this in mind, Hélice has designed innovative financial engineering based on blockchain technology to reduce the price of protheses – up to 50% – and thus meet the huge costs involved in the human reconstruction process.

Hélice is part of a “disruptive” approach to the sector, first by radically reducing prices for as many patients as possible to benefit from them, and then, by using the capital to invest substantially in order to improve these technologies.

Without Hélice intervention, such a process would normally be extremely slow given the particular factors of our sector as mentioned above. But thanks to Hélice, this process will be strongly speeded up and 2030 will be the new 2050 !


The Hélice token maximum supply is 1 Unit and can be divided up to 18 decimals.

The Hélice system is continuously fed with liquidity from the real economy (see figure 2 in the Lite Paper).

Hélice can reduce the cost of prostheses and other artificial organs by 30%, 40% or 50% without any change on the prosthesis !

The Hélice token will be exchanged in the Hélice platform which will be totally transparent and audited.

Every time a prosthesis is sold, a Buy-Back and Burn is performed, thus progressively reducing the total supply overtime. 

Hélice will have a discretionary right on 1 to 10% of the amount of daily exchanges in order to achieve gains to finance all prostheses.


Thanks to Hélice, more patients will benefit from prostheses that will greatly improve their lives. For instance, it shall help people who got one of their legs amputated recover some mobility, or improve the sight of those who have become blind etc,.

Heart, retina, arm prostheses and much more. All this for a fraction of the price that was previously required.

Over the long term, Hélice aims at extending life expectancy thanks to this technology.

The tokenomics has been divided into two parts: The Lite Paper and the Yellow Paper. Both are available in English and in French.


A first patient in 2021

Dylan was the first person to take advantage of the Hélice program, in an amount of 107,000€. This program allowed him to acquire the most sophisticated knee prosthesis in the world (Genium x3)

An exchange dedicated to the Hélice token



The owners of the Hélice token can earn 1.1% transaction fees. Indeed, transaction fees are the main source of revenue for almost all exchanges, but since Hélice earns money by selling prosthetics, a part of these fees will be given to users !



All Hélice transactions will be made available in real time, as well as the number of prostheses financed, buybacks and burns, etc.


Ergonomic Use

The exchange platform will allow the user to evolve safely and smoothly in an ecosystem entirely dedicated to the exchange of the Hélice token.

Our Advisors

Capture d’écran 2022-11-26 à 10.50.22

Bernard VERRIER | Ph.D in Molecular Virology

Born in France in 1957 and trained as a chemist, before getting a phD in molecular virology in 1985 and post-doctorated for three years at the EMBL, Germany, in retroviral oncology. Then, he moved to Lyon (France) to study human retrovirology, designing HIV vaccine candidates, either therapeutic, using tat,rev or nef regulatory proteins or prophylactic, with gp140 constructs, through a permanent position at CNRS. Director of research from CNRS since 2004, he was head of a joint unit between CNRS and bioMerieux, dedicated to HIV and HCV therapeutic vaccines, before beeing head of the department « Tissue biology and therapeutic engineering » at IBCP (www.ibcp.fr), in 2010, a joint unit between CNRS and University of Lyon. His research group is elaborating biodegradable particulate vaccines for human infectious diseases (HIV, HSV, Flu & HBV) using innate immunity ligands as adjuvants or therapeutic tools, and colloidal vectors for delivery of either proteins or nucleic acids, with a strong emphasis on tracking in animal models the journey of such vaccine vehicles. This expertise allows him to coordinate and to participate to various national and European research programs involving particulate vaccines and adjuvants, such as Cuthivac (www.cuthivac.eu), iNanoDCs (www.euronanomed.net) or Aditec (www.aditecproject.eu) programs.

Denis Chriqui-203040_Gallery

Denis CHRIQUI | Ph.D in economics

Economist and former professional trader. After a doctorate in economics from the University of Montpellier and training at the Wharton School, Denis was for more than 16 years a business buyer, professor of economics, specialist and researcher in behavioral finance, trainer in technical analysis and director of an import-export company. He worked as a professional trader in New York at Herzog Heine Geduld (Merrill Lynch) and E Trade for more than 6 years as an arbitrageur-strategist on derivatives, then in portfolio management and front office manager . Denis has devoted himself since 2004 to his vocation for teaching and proprietary trading.

Our Partners


Blockchain Lab - Startup Studio


Biotech company

In the press

We support them

E-Nable France


Club 1000 Handicap International


LIMITED OFFER : Sign up to earn bounties !



842 AV DU HUIT MAI 1945 83130 LA GARDE